Trial Profile
A phase III trial of thymosin beta-4 in patients with epidermolysis bullosa
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2019
Price :
$35
*
At a glance
- Drugs Timbetasin (Primary)
- Indications Epidermolysis bullosa
- Focus Registrational; Therapeutic Use
- Sponsors G-treeBNT
- 29 Jul 2019 According to a RegeneRx Biopharmaceuticals media release, this trial is expected to be initiated in 2020.
- 29 Oct 2018 According to a RegeneRx Biopharmaceuticals media release, this trial is expected to be initiated in 2019.
- 14 Feb 2018 Planned initiation date changed from 1 Jul 2017 to 1 Jan 2018, according to a RegeneRx Biopharmaceuticals media release.